AU2024290776A1 — Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor
Assigned to Orszagos Onkologiai Intezet · Expires 2026-01-15 · 0y expired
What this patent protects
The invention relates to cystathionine-γ-lyase (CSE) inhibitor for use in the treatment of a cancer, preferably a tumor in a patient, in combination with a (one or more) MAPK inhibitor, in particular an inhibitor of a BRAF V600 mutant, preferably for use in the prevention or dela…
USPTO Abstract
The invention relates to cystathionine-γ-lyase (CSE) inhibitor for use in the treatment of a cancer, preferably a tumor in a patient, in combination with a (one or more) MAPK inhibitor, in particular an inhibitor of a BRAF V600 mutant, preferably for use in the prevention or delaying the onset or development of resistance of said patient to a treatment of said cancer with the MAPK inhibitor, in particular the inhibitor of the BRAF V600 mutant. The invention also relates to combination treatments, if desired with diagnosis, as well as pharmaceutical compositions, combinations and kits for such therapies.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.